Does granulocyte colony stimulating factor have protective effects against carbon monoxide-induced apoptosis?

Carbon monoxide (CO) produced by incomplete combustion of hydrocarbons, has many toxic effects on different organs, especially the heart and brain that have greater demands for oxygen. The present study aimed to evaluate the protective effects of granulocyte colony stimulating factor (G-CSF) on apoptosis after CO poisoning in rats. Male Wistar rats were exposed to CO 1500 or 3000 ppm for 60 min. Single and multiple doses of G-CSF (10, 50, and 100 μg/kg) were administered to animals. After CO poisoning, carboxyhemoglobin concentration was measured, apoptotic cells were evaluated by TUNEL assay and caspase 3 activity was determined by immunofluorescence. Blood levels of carboxyhemoglobin significantly increased following exposure to both 1500 and 3000 ppm concentrations of CO. However, carboxyhemoglobin levels were significantly higher following exposure to CO 3000 ppm compared to CO 1500 ppm (p?<?0.05). Differences in caspase 3 activity between G-CSF and control groups were significant and G-CSF could decrease apoptosis following CO 3000 ppm poisoning (p?<?0.001). TUNEL assay showed that in rats treat with 5 doses of G-CSF 100 μg/kg, apoptosis was significantly ameliorated compared to control rats and sham (rats that were not exposed to CO) group (p?<?0.05). Concerning caspase 3 activity and apoptosis rate, the best results were found in rats exposed to 3000 ppm and treated with G-CSF 100 μg/kg. In this study, we confirmed that CO poisoning leads to cardiomyocytes apoptosis which could be significantly reduced by G-CSF treatment.     

A randomized clinical trial on the antitumoral effects of low molecular weight heparin in the treatment of esophageal cancer

The current treatment approaches for esophageal cancer are associated with poor survival, and there are ongoing efforts to find new and more effective therapeutic strategies. There are several reports on the antitumoral effects of low-molecular-weight heparins (LMWHs). We have assessed the possible survival benefit of LMWHs in esophageal malignancies. This was a randomized, single-blind, multicenter, Phase II clinical trial on nonmetastatic esophageal cancer candidate for neoadjuvant chemoradiotherapy. Patients were randomly assigned to the chemoradiotherapy-only arm or chemoradiotherapy plus enoxaparin arm using 1:1 allocation. Radiotherapy was delivered in 1.8-Gy daily fractions to a dose of 50.4 Gy in both groups. Paclitaxel 50 mg/m² and carboplatin (AUC 2) were administered weekly, concurrent with radiotherapy. In the intervention group, patients received enoxaparin (40 mg) and chemoradiation daily. 4–6 weeks after treatment, all patients underwent esophagectomy. After a median follow up of 7 months, estimated 1 year disease-free survival (DFS) in the intervention group was 78.9% and was 70% in the control groups ( p = 0.5). Toxicity from the experimental treatment was minimal, and there were no treatment-related deaths. A pathologically complete response in intervention and control group was 64.8% and 62.5%, respectively ( p = 0.9). There was a nonsignificant trend toward improved survival by the addition of enoxaparin to the concurrent chemoradiotherapy regimen. However, 1 y DFS of both groups were high as expected. A longer follow-up and a larger sample size are required.     

The rhizosheath: a potential root trait helping plants to tolerate drought stress

Plant and Soil - Experimental data concerning possible trophic relationships between phorophytes and epiphytes are contradictory. Several studies have indirectly shown that epiphytes affect the...     

A genetic variant in CDKN2A/2B locus was associated with poor prognosis in patients with esophageal squamous cell carcinoma

Esophageal squamous cell carcinoma (ESCC) is among the leading causes of cancer related death. Despite of extensive efforts in identifying valid cancer prognostic biomarkers, only a very small number of markers have been identified. Several genetic variants in the 9p21 region have been identified that are associated with the risk of multiple cancers. Here, we explored the association of two genetic variants in the 9p21 region, CDKN2A/B, rs10811661, and rs1333049 for the first time in 273 subjects with, or without ESCC. We observed that the patients with ESCC had a higher frequency of a TT genotype for rs10811661 than individuals in the control group, and this polymorphism was also associated with tumor size. Moreover, a CC genotype for the rs1333049 polymorphism was associated with a reduced overall survival (OS) of patients with ESCC. In particular, patients with a CC (rs1333049) genotype had a significantly shorter OS (CC genotype: 34.5 ± 8.9 months vs. CG+GG: 47.7 ± 5.9 months; p value = 0.03). We have also shown the association of a novel genetic variant in CDKN2B gene with clinical outcome of patients with ESCC. Further investigations are warranted in a larger population to explore the value of emerging markers as a risk stratification marker in ESCC.     

Oxidative stress during the cryopreservation of Passiflora suberosa L. shoot tips using the V-Cryo-plate technique: determination of the critical stages of the protocol

Plant Cell, Tissue and Organ Culture (PCTOC) - Ceratostigma willmottianum Stapf is an endemic species of China. Although it has high ornamental and medical value, its use is greatly limited by the...